Roche Exorcizes Torcetrapib’s Ghost: CETP Candidate Starts Phase III

If those who do not learn from the past are condemned to repeat it, then Roche’s extensive study of Pfizer’s torcetrapib is the Swiss firm’s attempt to avoid a repeat of the first cholesterol ester transfer protein inhibitor’s performance.